CTCX Key Statistics, Chart & Performance
The current stock price of CTCX is 0.1973 USD. In the past month the price decreased by -41.64%. In the past year, price decreased by -93.31%.
CTCX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.7 | 412.54B | ||
| AMGN | AMGEN INC | 15.62 | 183.97B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.89 | 122.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 18.05 | 85.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 828.43 | 55.82B | ||
| INSM | INSMED INC | N/A | 37.54B | ||
| NTRA | NATERA INC | N/A | 35.11B | ||
| BIIB | BIOGEN INC | 11.17 | 27.42B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.09 | 21.69B | ||
| INCY | INCYTE CORP | 17.22 | 21.71B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About CTCX
Company Profile
Carmell Corp. is a regenerative medicine biotech company, which focuses on leveraging its core platform technology plasmabased bioactive material to stimulate tissue repair or growth after severe injury, disease or aging. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 9 full-time employees. The company went IPO on 2021-07-29. The firm utilizes the Carmell Secretome to support skin and hair health. The Carmell Secretome consists of a potent cocktail of growth factors and proteins extracted from allogeneic human platelets sourced from United States Food and Drug Administration-approved tissue banks. The firm has developed a novel micellar nanoparticle formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the harmful excipients that are used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. Additionally, Carmell’s micellar formulations do not utilize mineral or vegetable oils across their entire product line and are designed to be non-comedogenic. The firm is also developing a line of men’s products and a line of topical haircare products.
Company Info
CARMELL CORP
2403 Sidney Street, Suite 300
Pittsburgh PENNSYLVANIA US
Employees: 9
Phone: 14128948248
CARMELL CORP / CTCX FAQ
What does CARMELL CORP do?
Carmell Corp. is a regenerative medicine biotech company, which focuses on leveraging its core platform technology plasmabased bioactive material to stimulate tissue repair or growth after severe injury, disease or aging. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 9 full-time employees. The company went IPO on 2021-07-29. The firm utilizes the Carmell Secretome to support skin and hair health. The Carmell Secretome consists of a potent cocktail of growth factors and proteins extracted from allogeneic human platelets sourced from United States Food and Drug Administration-approved tissue banks. The firm has developed a novel micellar nanoparticle formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the harmful excipients that are used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. Additionally, Carmell’s micellar formulations do not utilize mineral or vegetable oils across their entire product line and are designed to be non-comedogenic. The firm is also developing a line of men’s products and a line of topical haircare products.
What is the current price of CTCX stock?
The current stock price of CTCX is 0.1973 USD. The price increased by 1.39% in the last trading session.
Does CARMELL CORP pay dividends?
CTCX does not pay a dividend.
What is the ChartMill technical and fundamental rating of CTCX stock?
CTCX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the employee count for CTCX stock?
CARMELL CORP (CTCX) currently has 9 employees.
Can you provide the market cap for CARMELL CORP?
CARMELL CORP (CTCX) has a market capitalization of 5.94M USD. This makes CTCX a Nano Cap stock.
CTCX Technical Analysis
CTCX Financial Highlights
Over the last trailing twelve months CTCX reported a non-GAAP Earnings per Share(EPS) of -1.91. The EPS decreased by -335.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1047.34% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |